CDEK
← All drugs Report issue

split virion influenza vaccine

Vaccineexperimental

Pandemrix is an influenza vaccine for influenza pandemics, such as the 2009 flu pandemic. The vaccine was developed by GlaxoSmithKline (GSK) and patented in September 2006. — Wikipedia

Clinical trial activity

64 trials · 24 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
48
Phase 3
35
Phase 4
9

Earliest trial started Jul 1, 2005 (NCT00306943)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • allantoic split inactivated seasonal flu vaccine
  • gsk1562902a
  • gsk2340269a
  • gsk2340272a
  • idflu
  • influsplit ssw
  • influsplit tetra
  • mutagrip
  • prepandrix

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07302256Phase 1Dec 16, 2025China National Biotec Group Co., Ltd, Government of China
NCT06824519Phase 1/Phase 2 (Phase 2)May 8, 2025Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
NCT06641180Phase 3Nov 4, 2024Sanofi-Aventis
NCT06602024Phase 3Sep 16, 2024Moderna Therapeutics
NCT06342349Phase 1Mar 30, 2024China National Biotec Group Co., Ltd, Government of China
NCT06049927Phase 3Sep 16, 2023Government of China, Sinovac Biotech Co., Ltd
NCT05779020Phase 3Apr 25, 2023Butantan Institute, Fundação Butantan
NCT05645900Phase 3Dec 31, 2022Ab&b Biotechnology Co., Ltd.
NCT05512494Phase 4Oct 15, 2022Government of China, Sinovac Biotech Co., Ltd
NCT05245552Phase 3Aug 8, 2022Government of China, Sinovac Biotech Co., Ltd
NCT05431725Phase 3Jul 14, 2022Pontificia Universidad Catolica de Chile, Sinovac Biotech Co., Ltd
NCT05389137Phase 4Mar 2, 2022Wuhan Institute of Biological Products Co., Ltd
NCT05739474Phase 3Jan 19, 2022St. Petersburg Research Institute of Vaccines and Sera
NCT05138705Phase 4Dec 13, 2021China National Biotec Group Co., Ltd, Government of China
NCT05212623Phase 1Oct 26, 2021Changchun Institute of Biological Products Co., Ltd., Government of China
NCT05232292Phase 4Oct 6, 2021Samara Regional Cardiology Dispensary
NCT05308212Phase 2/Phase 3 (Phase 3)Mar 4, 2021St. Petersburg Research Institute of Vaccines and Sera
NCT05470582Phase 3Feb 16, 2021St. Petersburg Research Institute of Vaccines and Sera
NCT05312294Phase 3Dec 7, 2020St. Petersburg Research Institute of Vaccines and Sera
NCT04537234Phase 3Nov 9, 2020Sanofi, Sanofi-Aventis
Showing 20 of 64 trials
Page 1 / 4

Organizations

Research & Development (24)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit272732005
St. Petersburg Research Institute of Vaccines and SeraAcademic/Hospital111132016
Government of ChinaGovernment7132021
China National Biotec Group Co., LtdFor profit4432020
Sanofi-AventisFor profit4322010
Sinovac Biotech Co., LtdFor profit4422022
Butantan InstituteAcademic/Hospital2212019
Fundação ButantanAcademic/Hospital2012019
SanofiFor profit2122010
University of LausanneAcademic/Hospital2212013
Ab&b Biotechnology Co., Ltd.Academic/Hospital1112022
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.For profit1112025
Changchun Institute of Biological Products Co., Ltd.For profit1012021
Clinical Trial Consultants ABFor profit1012018
Eurocine Vaccines ABFor profit1112018
Kazakh National Medical UniversityAcademic/Hospital1012016
Korea UniversityAcademic/Hospital1112011
Moderna TherapeuticsFor profit1112024
Pontificia Universidad Catolica de ChileAcademic/Hospital1012022
Research Institute for Biological Safety ProblemsAcademic/Hospital1112016
24 organizations
Page 1 / 2